11 completed, 5 terminated, 4 recruiting, 3 active not recruiting. 23 Phase 1, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 23 | Completed 11, Terminated 5, Recruiting 4, Active not recruiting 3 |
| Phase 2 | 12 | Completed 6, Terminated 3, Recruiting 2, Active not recruiting 1 |
Follow relatlimab: new trials by email Literature Review of relatlimab trials Research Report on relatlimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis Nivolumab and Relatlimab, Melphalan - Metastatic Melanoma, Liver Metastases | Phase 1 / Phase 2 | Recruiting | University of Wisconsin, Madison | 15 | 2026-11-01 | 2026-10-30 |
| Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY) Nivolumab, Relatlimab, Ipilimumab - Melanoma | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2024-12-31 | 2026-08-28 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma Relatlimab, Nivolumab - Lymphoma, Non-Hodgkin, Hodgkin Disease | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 5 | 2022-09-13 | 2026-06-26 |
| Study of Relatlimab in Combination With Nivolumab in Chinese Participants Relatlimab, Nivolumab - Advanced Solid Tumors | Phase 1 | Completed | Bristol-Myers Squibb | 6 | 2022-07-27 | 2024-02-20 |
| A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer Relatlimab, Nivolumab, Bevacizumab - Carcinoma, Hepatocellular | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 82 | 2022-05-05 | 2026-10-14 |
| Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors Zanzalintinib, Nivolumab, Ipilimumab - Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 1 | Recruiting | Exelixis | 1394 | 2021-12-14 | 2026-10-01 |
| A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment Relatlimab, Ipilimumab - Melanoma | Phase 1 | Terminated | Bristol-Myers Squibb | 11 | 2021-12-09 | 2024-07-24 |
| Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma Ipilimumab, Nivolumab, Pembrolizumab - Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8 | Phase 1 | Recruiting | Carlo Contreras | 36 | 2021-10-20 | 2026-07-13 |
| Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma SD-101, Nivolumab, Ipilimumab - Metastatic Uveal Melanoma in the Liver | Phase 1 | Terminated | TriSalus Life Sciences, Inc. | 67 | 2021-08-02 | 2025-10-22 |
| Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma Nivolumab, Relatlimab - Hepatocellular Carcinoma | Phase 1 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 31 | 2021-05-28 | 2026-10-28 |
| T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer Ipilimumab, Cyclophosphamid, Fludarabine Phosphate - Metastatic Ovarian Cancer, Metastatic Fallopian Tube Cancer | Phase 1 / Phase 2 | Terminated | Inge Marie Svane | 6 | 2021-04-22 | 2025-08-12 |
| Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT Elotuzumab, pomalidomide, dexamethasone, Anti-LAG-3, Anti-LAG-3 + Pomalidimide + Dexamethasone - Multiple Myeloma, Relapsed Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Multiple Myeloma Research Consortium | 14 | 2020-07-10 | 2025-02-14 |
| A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab relatlimab, nivolumab, rHuPH20 - Cancer | Phase 1 | Completed | Bristol-Myers Squibb | 24 | 2019-10-01 | 2023-04-06 |
| REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer Nivolumab, Relatlimab - Gastroesophageal Cancer, Immune Checkpoint Inhibition | Phase 1 / Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 21 | 2019-03-06 | 2026-05-06 |
| Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade Nivolumab, BMS-986016 - Glioblastoma | Phase 1 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 21 | 2018-09-24 | 2024-07-24 |
| An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread Relatlimab, Nivolumab, BMS-986205 - Advanced Cancer | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 229 | 2018-05-30 | 2026-04-06 |
| An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment Nivolumab, Relatlimab, Cabiralizumab - Advanced Cancer | Phase 1 | Completed | Bristol-Myers Squibb | 20 | 2018-05-07 | 2022-09-26 |
| A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies JCAR017, Durvalumab, CC-122 - Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse | Phase 1 / Phase 2 | Completed | Celgene | 62 | 2017-12-20 | 2024-04-04 |
| Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer Nivolumab, Relatlimab, Carboplatin - Gastric Cancer, Esophageal Cancer | Phase 1 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 32 | 2017-07-11 | 2026-03-23 |
| Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors Relatlimab, Nivolumab - Cancer | Phase 1 | Completed | Bristol-Myers Squibb | 35 | 2017-01-04 | 2025-02-17 |
Showing 20 of 23. Sign in to see all of them.
Melanoma (4) · Carcinoma, Hepatocellular (3) · Lymphoma, Non-Hodgkin (3) · Hodgkin Disease (2) · Liver Neoplasms (2) · Lymphoma, Large B-Cell, Diffuse (2) · Neoplasms (2) · Recurrence (2) · Brain Neoplasms (1) · Burkitt Lymphoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1)
Bristol-Myers Squibb (11) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Carlo Contreras (1) · Celgene (1) · Exelixis (1) · Inge Marie Svane (1) · M.D. Anderson Cancer Center (1) · Multiple Myeloma Research Consortium (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · TriSalus Life Sciences, Inc. (1) · University of Wisconsin, Madison (1)
United States (20) · Spain (7) · France (6) · Italy (6) · Australia (5) · Germany (5) · United Kingdom (5) · Canada (4) · Japan (4) · Belgium (3) · Netherlands (3) · Switzerland (3) · Austria (2) · China (2) · Denmark (2)
Vincent Lam, MD (2) · Carlo M Contreras, MD (1) · Hearn J. Cho, M.D., Ph.D. (1) · Hussein Tawbi, MD,PHD (1) · Inge Marie Svane, Prof., M.D. (1) · Madhav V. Dhodapkar, M.D. (1) · Mark Yarchoan, MD (1) · Sadhana Jackson, M.D. (1) · Tine J Monberg, M.D. (1) · Vincent Ma, MD (1)
PMID 30170630, PMID 31487218, PMID 32324435, PMID 33277223, PMID 34083421, PMID 34515338, PMID 35969233, PMID 36719749, PMID 36780608, PMID 38340723, PMID 38504015, PMID 38608691, PMID 39187595, PMID 39889250, PMID 40010775, PMID 40030000, PMID 40389374
2023 (3), 2015 (1), 2018 (1), 2019 (1)